# PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

> **NCT04052737** · PHASE2 · COMPLETED · sponsor: **Pharmazz, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Alzheimer Disease
- Dementia

## Interventions

- **DRUG:** Normal Saline along with standard treatment
- **DRUG:** PMZ-1620 (sovateltide) along with standard treatment

## Key facts

- **NCT ID:** NCT04052737
- **Lead sponsor:** Pharmazz, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-23
- **Primary completion:** 2022-12-20
- **Final completion:** 2023-01-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052737, "PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04052737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*